Med-tech tourism startup CureMeAbroad has raised $600K in a pre-seed round, marking a strong step forward in the rapidly evolving D2C ecosystem India. As part of ongoing Indian D2C updates and D2C startup news, the round saw participation from notable investors including Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna, and Vikrant Potnis, highlighting growing interest in tech-enabled healthcare platforms.
Founded in June 2025 by Aditya Oza and Mikhail Bohra, CureMeAbroad is building an AI-first discovery platform that connects international patients directly with hospitals, surgeons, and treatment destinations. This approach reflects a new-age direct-to-consumer India model in healthcare, where platforms are simplifying complex decision-making journeys and improving transparency for global patients.
Operating in a market projected to reach $174 billion by 2035, CureMeAbroad is positioning itself among the latest D2C startups transforming healthcare access. The platform addresses key industry challenges such as lack of trust, opaque pricing, dependence on intermediaries, and fragmented patient experiences—issues that align with broader D2C consumer behavior India trends where users increasingly demand clarity, convenience, and reliability.
At the core of CureMeAbroad’s offering is its proprietary AI cost estimator, trained on over 634 procedure records, alongside advanced clinical matching models and a multilingual patient intelligence layer. These capabilities highlight the role of D2C supply chain innovation and technology in reshaping healthcare discovery, making the platform both scalable and efficient.
Currently, the company hosts a directory of more than 6,000 hospitals across 47 countries and 45 specialties, while actively working with over 380 accredited partner hospitals in key medical tourism hubs such as India, Turkey, Thailand, Mexico, and Georgia. This extensive network strengthens its position within the global D2C ecosystem India narrative, where cross-border services are becoming increasingly relevant.
The newly raised capital will be deployed towards further technology investments, enhancing AI capabilities, and accelerating market expansion. As part of its D2C expansion plans, CureMeAbroad is targeting high-potential regions including the GCC, UK, and Africa—markets with growing demand for affordable and high-quality medical treatments.
From a D2C business model India perspective, CureMeAbroad represents a shift toward platform-driven healthcare ecosystems, where data, technology, and direct access converge to create better outcomes. Its focus on transparency and patient-centric design also aligns with D2C brand building stories that prioritize trust and long-term engagement.
In terms of competition, the startup operates alongside global platforms such as Bookimed, PlacidWay, and Medical Departures. However, its AI-first approach and focus on verified, structured discovery position it uniquely within the D2C industry news landscape.
As part of the daily digest of D2C news in India, CureMeAbroad’s journey reflects what’s happening in India’s D2C space today—technology-driven disruption, global ambition, and strong investor interest in scalable, impact-driven platforms. The rise of such VC-backed D2C brands indicates a broader shift where healthcare is becoming more accessible, transparent, and digitally enabled.
Overall, CureMeAbroad is not just building a platform; it is redefining how patients discover and access global healthcare, positioning itself as a promising player in the emerging D2C healthcare and medical tourism ecosystem.
